The ST2/IL-33 Pathway in Adult and Paediatric Heart Disease and Transplantation

Brunetti, Giacomina; Barile, Barbara; Nicchia, Grazia Paola; Luciani, Giovanni Battista; Galeone, Antonella

doi:10.3390/biomedicines11061676

Cited by 7 publications

(5 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several biomarkers have been proposed to detect and monitor allograft rejection after HT. The ST2/IL-33 pathway has been shown to be involved in the context of acute rejection after HT in both adults and pediatric heart recipients [36,37]. Serum sST2 levels significantly rise in the context of acute rejection showing a linear association with severity of acute rejection and decline after successful rejection therapy [38,39].…”

Section: Discussionmentioning

confidence: 99%

Ten-Year Experience with Endomyocardial Biopsy after Orthotopic Heart Transplantation: Comparison between Trans-Jugular and Trans-Femoral Approach

Galeone,

Bernabei,

Pesarini

et al. 2024

JCDD

Self Cite

View full text Add to dashboard Cite

Background: Endomyocardial biopsy (EMB) is considered the gold standard for monitoring allograft rejection after heart transplantation. EMB is an invasive procedure that may be performed via a trans-jugular or a trans-femoral approach with a complication rate reported as less than 6%. The aim of this study was to evaluate the complication rate after EMBs in heart recipients and to compare the results of EMBs performed via a trans-jugular or a trans-femoral approach. Methods: Medical records of heart recipients undergoing EMBs between January 2012 and December 2022 were retrospectively reviewed. EMB-related complications were classified as major (death, pericardial effusion, hemopericardium, cardiac tamponade requiring a pericardiocentesis or an urgent cardiac surgery, ventricular arrythmias, permanent atrio-ventricular block requiring permanent pacing, hemothorax, pneumothorax and retroperitoneal bleeding) and minor (de novo tricuspid regurgitation, arrhythmias, coronary artery fistula, vascular access site complications). Results: A total of 1698 EMBs were performed during the study period at our institution in 212 heart recipients. There were 927 (55%) EMBs performed through a trans-jugular approach (TJ group) and 771 (45%) EMBs performed through a trans-femoral approach (TF group). A total of 60 (3.5%) complications were recorded, including nine (0.5%) major complications (six cardiac tamponades, two pneumothorax and one retroperitoneal bleeding) and 51 (3%) minor complications (seven coronary fistulae, five de novo tricuspid regurgitation, four supraventricular arrythmias and thirty-five vascular access site complications). No difference was found in total (38 [4%] vs. 22 [3%]; p = 0.16) and major (6 [1%} vs. 3 [0.4%]; p = 0.65) complications (32 [3%] vs. 19 [2%]; p = 0.23) between the TJ group and the TF group. No difference was found in male sex, age at time of EMB and time from HT between complicated and not complicated EMBs. Conclusions: EMBs represent a safe procedure with a low risk of complications. In our experience, EMBs performed via a trans-jugular approach are as safe as the trans-femoral approach.

show abstract

Section: Discussionmentioning

confidence: 99%

Ten-Year Experience with Endomyocardial Biopsy after Orthotopic Heart Transplantation: Comparison between Trans-Jugular and Trans-Femoral Approach

Galeone,

Bernabei,

Pesarini

et al. 2024

JCDD

Self Cite

View full text Add to dashboard Cite

show abstract

“… 45 , 52 , 53 In children, this emerging cardiovascular biomarker has been studied in small cohorts with similar associations of increased IL-1 RL1 levels in patients with worsening heart function. 14 , 54 , 55 To our knowledge, no previous study has addressed its role in neonates with high-risk CHD and no quantitative assay to measure IL-1 RL1 in DBS samples has been reported. This study emphasizes the emerging importance of IL-1 RL1 as a novel biomarker in newborns with CHD.…”

Section: Discussionmentioning

confidence: 99%

“…The role of IL-1 RL1 in projecting the risk of adverse events in adults with heart failure appears to be independent of natriuretic peptides, with higher IL-1 RL1 levels associated with increased cardiovascular mortality based on established reference ranges . In children, this emerging cardiovascular biomarker has been studied in small cohorts with similar associations of increased IL-1 RL1 levels in patients with worsening heart function . To our knowledge, no previous study has addressed its role in neonates with high-risk CHD and no quantitative assay to measure IL-1 RL1 in DBS samples has been reported.…”

Section: Discussionmentioning

confidence: 99%

Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis

Clausen,

Friberg,

Lannering

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceCongenital heart disease (CHD) is the most common human organ malformation, affecting approximately 1 of 125 newborns globally.ObjectivesAssessing the performance of 2 diagnostic tests using minimal amounts of dried blood spots (DBS) to identify high-risk CHD compared with controls in a Swedish cohort of neonates.Design, Setting, and ParticipantsThis diagnostic study took place in Sweden between 2019 and 2023 and enrolled full-term babies born between 2005 and 2023. All cases were identified through centralized pediatric cardiothoracic surgical services in Lund and Gothenburg, Sweden. Controls were followed up for 1 year to ensure no late presentations of high-risk CHD occurred. Cases were verified through surgical records and echocardiography.ExposureHigh-risk CHD, defined as cases requiring cardiac surgical management during infancy due to evolving signs of heart failure or types in which the postnatal circulation depends on patency of the arterial duct. Using 3-μL DBS samples, automated quantitative tests for NT-proBNP and interleukin 1 receptor-like 1 (IL-1 RL1; formerly known as soluble ST2) were compared against established CHD screening methods.Main Outcomes and MeasuresPerformance of DBS tests to detect high-risk CHD using receiver operating characteristic curves; Bland-Altman and Pearson correlation analyses to compare IL-1 RL1 DBS with plasma blood levels.ResultsA total of 313 newborns were included (mean [SD] gestational age, 39.4 [1.3] weeks; 181 [57.8%] male). Mean (SD) birthweight was 3495 (483) grams. Analyzed DBS samples included 217 CHD cases and 96 controls. Among the CHD cases, 188 participants (89.3%) were high-risk types, of which 73 (38.8%) were suspected prenatally. Of the 188 high-risk cases, 94 (50.0%) passed pulse oximetry screening and 36 (19.1%) were initially discharged after birth without diagnoses. Combining NT-proBNP and IL-1 RL1 tests performed well in comparison with existing screening methods and enabled additional identification of asymptomatic babies with receiver operating characteristic area under the curve 0.95 (95% CI, 0.93-0.98).Conclusions and relevanceIn this diagnostic study, NT-proBNP and IL-1 RL1 DBS assays identified high-risk CHD in a timely manner, including in asymptomatic newborns, and improved overall screening performance in this cohort from Sweden. Prospective evaluation of this novel approach is warranted.

show abstract

“…ST2 is a member of the interleukin-1 receptor family that can be found as soluble and membrane-bound forms [ 46 ]. Its ligand is represented by IL-33, and the IL-33/ST2 interaction has a protective effect against fibrosis and myocardial hypertrophy [ 47 ].…”

Section: Fibrosismentioning

confidence: 99%

Cellular and Molecular Mechanisms Activated by a Left Ventricular Assist Device

Galeone,

Buccoliero,

Barile

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

Left ventricular assist devices (LVADs) represent the final treatment for patients with end-stage heart failure (HF) not eligible for transplantation. Although LVAD design has been further improved in the last decade, their use is associated with different complications. Specifically, inflammation, fibrosis, bleeding events, right ventricular failure, and aortic valve regurgitation may occur. In addition, reverse remodeling is associated with substantial cellular and molecular changes of the failing myocardium during LVAD support with positive effects on patients’ health. All these processes also lead to the identification of biomarkers identifying LVAD patients as having an augmented risk of developing associated adverse events, thus highlighting the possibility of identifying new therapeutic targets. Additionally, it has been reported that LVAD complications could cause or exacerbate a state of malnutrition, suggesting that, with an adjustment in nutrition, the general health of these patients could be improved.

show abstract

The ST2/IL-33 Pathway in Adult and Paediatric Heart Disease and Transplantation

Cited by 7 publications

References 121 publications

Ten-Year Experience with Endomyocardial Biopsy after Orthotopic Heart Transplantation: Comparison between Trans-Jugular and Trans-Femoral Approach

Ten-Year Experience with Endomyocardial Biopsy after Orthotopic Heart Transplantation: Comparison between Trans-Jugular and Trans-Femoral Approach

Newborn Screening for High-Risk Congenital Heart Disease by Dried Blood Spot Biomarker Analysis

Cellular and Molecular Mechanisms Activated by a Left Ventricular Assist Device

Contact Info

Product

Resources

About